Evkeeza

Active Ingredient(s): Evinacumab-dgnb
FDA Approved: * February 11, 2021
Pharm Company: * REGENERON PHARMACEUTICALS
Category: Cholesterol

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Evkeeza Overview

Evinacumab, sold under the brand name Evkeeza, is a monoclonal antibody medication for the treatment of homozygous familial hypercholesterolemia (HoFH).[1][2] Common side effects include nasopharyngitis (cold), influenza-like illness, dizziness, rhinorrhea (runny nose), and nausea. Serious hypersensitivity (allergic) reactions have occurred in the Evkeeza clinical trials.[2] Evinacumab binds to the angiopoietin-like protein 3 (ANGPTL3).[...

Read more Evkeeza Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Evinacumab

Recent Evkeeza Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Evinacumab-dgnb
  • Solution: 1200mg/8ml, 345mg/2.3ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Evkeeza: (2 results)

Sorted by National Drug Code
  • 61755-010 Evkeeza 150 mg/ml Intravenous Injection, Solution, Concentrate by Regeneron Pharmaceuticals, Inc.
  • 61755-013 Evkeeza 150 mg/ml Intravenous Injection, Solution, Concentrate by Regeneron Pharmaceuticals, Inc.

Other drugs which contain Evinacumab-dgnb or a similar ingredient: (1 result)